Skip to main content
. Author manuscript; available in PMC: 2022 Jul 1.
Published in final edited form as: Neurol Sci. 2020 Nov 22;42(7):2911–2919. doi: 10.1007/s10072-020-04910-8

Fig. 3.

Fig. 3

Males (a; t(21)=1.970, p=0.0698) and females (c; t(37)=5.074, p<0.0001) administered Ex-4 during probe trials completed fewer trials than their respective controls, although this reached significance only in females. The GLP-1R agonist did not alter the total number of reversals in probe trials in males (b; t(21)=0.6041, p=0.5522) but did non-significantly decrease the number of reversals in females (d; t(37)=1.939, p=0.0603). † p<0.1; **** p<0.0001